2,083 reports of this reaction
8.5% of all PALIVIZUMAB reports
#1 most reported adverse reaction
RESPIRATORY SYNCYTIAL VIRUS INFECTION is the #1 most commonly reported adverse reaction for PALIVIZUMAB, manufactured by Swedish Orphan Biovitrum AB (publ). There are 2,083 FDA adverse event reports linking PALIVIZUMAB to RESPIRATORY SYNCYTIAL VIRUS INFECTION. This represents approximately 8.5% of all 24,586 adverse event reports for this drug.
Patients taking PALIVIZUMAB who experience respiratory syncytial virus infection should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RESPIRATORY SYNCYTIAL VIRUS INFECTION is moderately reported among PALIVIZUMAB users, representing a notable but not dominant share of adverse events.
In addition to respiratory syncytial virus infection, the following adverse reactions have been reported for PALIVIZUMAB:
The following drugs have also been linked to respiratory syncytial virus infection in FDA adverse event reports:
RESPIRATORY SYNCYTIAL VIRUS INFECTION has been reported as an adverse event in 2,083 FDA reports for PALIVIZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
RESPIRATORY SYNCYTIAL VIRUS INFECTION accounts for approximately 8.5% of all adverse event reports for PALIVIZUMAB, making it one of the most commonly reported side effect.
If you experience respiratory syncytial virus infection while taking PALIVIZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.